Scilex Holding Presents Post-Hoc Analysis of C.L.E.A.R. Trial On Clinical Meaningfulness Of Safety And Efficacy Of SP-102 For Treatment of Lumbosacral Radicular Pain at ASIPP 2025

Author: Benzinga Newsdesk | May 16, 2025 08:21am

Scilex Holding Company (NASDAQ:SCLX, "Scilex" or "Company"))), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today presented the presentation of post-hoc analysis of the C.L.E.A.R. trial (Corticosteroid Lumbar Epidural Analgesia in Radiculopathy) interpreting clinical meaningfulness of safety and efficacy of SP-102 (SEMDEXA™) for the treatment of lumbosacral radicular pain (LRP) at the 27th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP), May 15-17, 2025 in Orlando, FL.

Posted In: SCLX